Innoviva (INVA) has entered a deal to acquire all the outstanding shares of Entasis Therapeutics Holdings (ETTX) it doesn't already own for $2.20 each in...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Entasis Therapeutics Holdings (ETTX) has an average rating of outperform and price targets ranging from $1.80 to $5, according to analysts polled by...
Protagonist Therapeutics (PTGX) shares slumped 33% after the company reported topline data from a phase 2 trial of PN-943 in ulcerative colitis. InMed...
| Address | 35 Gatehouse Park Drive Waltham, Massachusetts 02451 |
| Phone | +1.781.810.0120 |
| Number of Employees | 33 |
| Recent SEC Filing | 06/17/2022 SC 13E3/A |
| President, Chief Executive Officer & Director | Manoussos Perros |
| VP, Chief Financial & Accounting Officer | Kristie Wagner |
| Chief Scientific Officer | Ruben Tommasi |
| Chief Medical Officer | David Altarac |
| Price Open | $2.18 |
| Previous Close | $2.19 |
| 52 Week Range | $1.40 - 3.88 |
| Market Capitalization | $105.3 M |
| Shares Outstanding | 47.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.12 |
| Beta vs. S&P 500 | N/A |
| Revenue | $5.0 M |
| Net Profit Margin | N/A |
| Return on Equity | -145.48% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
